KAIROS PHARMA, LTD. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
KAIROS PHARMA, LTD. (KAPA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 5.05 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- KAIROS PHARMA, LTD. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 5.05M shares, a 8.52% increase year-over-year.
- KAIROS PHARMA, LTD. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 4.66M shares, a 3004.52% increase year-over-year.
- KAIROS PHARMA, LTD. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 150.00K shares.
- KAIROS PHARMA, LTD. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.05M shares, a 1022.56% increase from fiscal 2024.
- KAIROS PHARMA, LTD. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 450.19K shares, a 200.13% increase from fiscal 2023.
- KAIROS PHARMA, LTD. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 150.00K shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 5.05M shares 10-Q · filed 2026-08-12 | |||||
| 2026-03-31 | 5.05M shares 10-Q · filed 2026-05-13 | |||||
| 2025-12-31 | 5.05M shares 10-K · filed 2026-03-31 | |||||
| 2025-09-30 | 4.33M shares 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | 4.20M shares 10-Q · filed 2026-08-12 | |||||
| 2025-03-31 | 4.66M shares 10-Q · filed 2026-05-13 | |||||
| 2024-12-31 | 450.19K shares 10-K · filed 2026-03-31 | 278.19K shares 10-K · filed 2025-04-15 | ||||
| 2024-09-30 | 358.19K shares 10-Q · filed 2025-11-14 | 278.19K shares 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | 150.00K shares 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | 150.00K shares 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | 150.00K shares 10-K · filed 2025-04-15 | |||||
| 2023-09-30 | 150.00K shares 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |